Half-Life Extension Through HESylation®

Therapeutic Proteins: Strategies to Modulate Their Plasma Half-Lives

Volumn , Issue , 2012, Pages 117-140

  Hey, Thomas ^a   Knoller, Helmut ^a   Vorstheim, Peter ^a  

^a Fresenius Kabi Deutschland GmbH   (Germany)

Author keywords

Biodegradable polymer; Erythropoietin; Half life extension; HESylation; Hydroxyethyl starch; PEGylated interferon alpha; Protein conjugates; Protein coupling; Therapeutic proteins; Viscosity

Indexed keywords

EID: 84865473733     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527644827.ch7     Document Type: Chapter

References (39)

1. Veronese, F.M., and Pasut, G. (2005) PEGylation, successful approach to drug delivery . Drug Discov. Today, 10, 1451-1458.
2. Webster, R., Elliott, V., Park, B.K., Walker, D., Hankin, M., and Taupin, P. (2009) PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals, in Pegylated Protein Drugs: Basic Science and Clinical Applications (ed. Veronese, F.M.), Birkhäuser Verlag, Basel, pp. 127-146 .
3. Armstrong, J.K., Hempel, G., Koling, S., Chan, L.S., Fisher, T., Meiselman, H.J., and Garratty, G. (2007) Antibody against poly(ethylene glycol) adversely affects PEG - asparaginase therapy in acute lymphoblastic leukemia patients . Cancer, 110, 103-111 .
4. European Pharmacopeia (2010) Hydroxyethylstarch monograph 1785 .
5. Finfer, S., Liu, B., Taylor, C., Bellomo, R., Billot, L., Cook, D., Du, B., McArthur, C., and Myburgh, J. (2010) Resuscitation fl uid use in critically ill adults: an international cross - sectional study in 391 intensive care units . Crit. Care, 14, R185 .
6. Neff, T.A., Doelberg, M., Jungheinrich, C., Sauerland, A., Spahn, D.R., and Stocker, R. (2003) Repetitive large - dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury . Anesth. Analg., 96, 1453-1459 . table.
7. Westphal, M., James, M.F., Kozek - Langenecker, S., Stocker, R., Guidet, B., and Van, A.H. (2009) Hydroxyethyl starches: different products-different effects . Anesthesiology, 111, 187-202 .
8. Kiehl, P., Metze, D., Kresse, H., Reimann, S., Kraft, D., and Kapp, A. (1998) Decreased activity of acid alpha - glucosidase in a patient with persistent periocular swelling after infusions of hydroxyethyl starch . Br. J. Dermatol., 138, 672-677 .
9. Ständer, S., Szepfalusi, Z., Bohle, B., Ständer, H., Kraft, D., Luger, T.A., and Metze, D. (2001) Differential storage of hydroxyethyl starch (HES) in the skin: an immunoelectron - microscopical long - term study . Cell Tissue Res., 304, 261-269 .
10. Jaeger, K., J ü ttner, B., Heine, J., Ruschulte, H., Scheinichen, D., and Piepenbrock, S. (2000) Effects of hydroxyethyl starch and modifi ed fl uid gelatine on phagocytic activity of human neutrophils and monocytes-results of a randomized, prospective clinical study . Infus. Ther. Transfus. Med., 27, 256-260 .
11. Nohe, B., Burchard, M., Zanke, C., Eichner, M., Krump - Konvalinkova, V., Kirkpatrick, C.J., and Dieterich, H.J. (2002) Endothelial accumulation of hydroxyethyl starch and functional consequences on leukocyte - endothelial interactions . E ur. Surg. Res., 34, 364-372 .
12. Szepfalusi, Z., Parth, E., Jurecka, W., Luger, T.A., and Kraft, D. (1993) Human monocytes and keratinocytes in culture ingest hydroxyethylstarch . Arch. Dermatol. Res., 285, 144-150.
13. Laxenaire, M.C., Charpentier, C., and Feldman, L. (1994) [Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study] . Ann. Fr. Anesth. Reanim., 13, 301-310.
14. Dieterich, H.J., Kraft, D., Sirtl, C., Laubenthal, H., Schimetta, W., Polz, W., Gerlach, E., and Peter, K. (1998) Hydroxyethyl starch antibodies in humans: incidence and clinical relevance . Anesth. Analg., 86, 1123-1126.
15. Richter, A.W., and de Belder, A.N. (1976) Antibodies against hydroxyethylstarch produced in rabbits by immunization with a protein - hydroxyetylstarch conjugate . I nt. Arch. Allergy Appl. Immunol., 52, 307-314.
16. Abuchowski, A., van Es, T., Palczuk, N.C., and Davis, F.F. (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol . J. Biol. Chem., 252, 3578-3581.
17. Beez, Michael and Rothe, Wolfgang (1976) Kolloidales Volumenersatzmittel aus Hydroxyaethylstaerke und Haemoglobin. Dr. Eduard Fresenius, Chemischpharmazeutische Industrie KG. DE Patent 2616086.1., filed 13.04.1976 and issued 03.04. 1986.
18. Wong, Jeffrey Tze - Fei (1976) Blood substitute based on hemoglobin. Hematech Inc. US Patent 4064118, fi led 08.10.1976 and issued 20.12. 1977.
19. Baldwin, J.E., Gill, B., Whitten, J.P., and Taegtmeyer, H. (1981) Synthesis of polymer - bound hemoglobin samples . Tetrahedron, 37, 1723-1726.
20. Cerny, L.C., Stasiw, D.M., Cerny, E.L., Baldwin, J.E., and Gill, B. (1982) A hydroxyethyl starch - hemoglobin polymer as a blood substitute . Clin. Hemorheol., 2, 355-365.
21. Lee, C.R., McKenzie, C.A., Webster, K.D., and Whaley, R. (1991) Pegademase bovine: replacement therapy for severe combined immunodefi ciency disease . DICP: The Annals of Pharmacotherapy, 25, 1092-1095.
22. Maout, E., Grandgeorge, M., and Dellacherie, E. (1993) Hydroxyethylstarch conjugated to human hemoglobin for use in blood transfusion: comparison with Dextran conjugates, in Carbohydrates and Carbohydrate Polymers (ed. Yalpani, M.), ATL Press, Shrewsbury, pp. 132-140.
23. Sommermeyer, Klaus and Eichner, Wolfram (1997) Haemoglobin - Hydroxyethyl Starch conjugates as oxygen carriers. Fresenius AG. EP Patent 0912197, fi led 07.07.1997 and issued 05.12.2001.
24. Sommermeyer, Klaus (2005) Method for producing conjugates of polysaccharides and polynucleotides. Noxxon Pharma AG, Supramol Parenteral Colloid GmbH. Patent application WO2005/074993, filed 08.02.2005.
25. Sommermeyer, Klaus, Eichner, Wolfram, Frie, Sven, Jungheinrich, Cornelius, Scharpf, Roland, Lutterbeck, Katharina, Hemberger, J ü rgen, and Orlando, Michele (2002) Conjugates of hydroxyalkyl starch and an active agent. Fresenius Kabi Deutschland GmbH. US Patent 7816516, fi led 15.03.2002 and issued 19.10.2010.
26. Conradt, Harald S., Grabenhorst, Eckart, Nimtz, Manfred, Zander, Norbert, Frank, Ronald, and Eichner, Wolfram (2003). HASylated polypeptides, especially HASylated erythropoietin. Fresenius Kabi Deutschland GmbH. EP Patent 1398322, fi led 11.09.2003 and issued 19.04.2006.
27. Zander, Norbert (2003) Method of producing hydroxyalkyl starch derivatives. Fresenius Kabi Deutschland GmbH. EP Patent 1398327, fi led 11.09.2003 and issued 27.08.2008.
28. Zander, Norbert, Eichner, Wolfram and Conradt, Harald (2003) Hydroxyalkyl starch derivatives. Fresenius Kabi Deutschland GmbH. EP Patent 1398328, fi led 11.09.2003 and issued 18.11.2009.
29. Bentley, Michael David, and Harris, J. Milton (1998) Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines. Shearwater Corp. US Patent 5,990,237, fi led 20.05.1998 and issued 23.11.1999.
30. Hacket, Frank, Hey, Thomas, Hauschild, Franziska, Knoller, Helmut, Schimmel, Martin, and Sommermeyer, Klaus (2009). Hydroxyalkyl starch derivatives and process for their preparation. Fresenius Kabi Deutschland GmbH. Patent application WO2009/077154.
31. Besheer, A., Hertel, T.C., Kressler, J., Mader, K., and Pietzsch, M. (2009) Enzymatically catalyzed HES conjugation using microbial transglutaminase: Proof of feasibility . J. Pharm. Sci., 98, 4420-4428.
32. Frank, Hans - Georg, and Haberl, Udo (2006) Supravalent Compounds. Aplagen Deutschland GmbH. Patent application PCT/EP2006/006097, fi led 23.06.2006. 23 - 6 - 2006.
33. Adamson, Gord, Bell, David, and Brookes, Steven (2009). Polysaccharide - protein conjugates reversibly coupled via imine bonds. Therapure Biopharma Inc. Patent application PCT/CA2009/000885, fi led 26.06.2009.
34. McDougall Iain, C. (2006) Recent advances in erythropoietic-agents in renal anemia . Semin. Nephrol., 26, 313-318.
35. Jarsch, M., Brandt, M., Lanzendorfer, M., and Haselbeck, A. (2008) Comparative erythropoietin receptor binding kinetics of C.E.R.A. and epoetin - beta determined by surface plasmon resonance and competition binding assay . Pharmacology, 81, 63-69.
36. Syed, R.S., Reid, S.W., Li, C., Cheetham, J.C., Aoki, K.H., Liu, B., Zhan, H., Osslund, T.D., Chirino, A.J., Zhang, J., Finer-Moore, J., Elliott, S., Sitney, K., Katz, B.A., Matthews, D.J., Wendoloski, J.J., Egrie, J., and Stroud, R.M. (1998) Effi ciency of signalling through cytokine receptors depends critically on receptor orientation . Nature, 395, 511-516.
37. Egrie, J.C., and Browne, J.K. (2001) Development and characterization of novel erythropoiesis stimulating protein (NESP) . Br. J. Cancer, 84 (Suppl. 1), 3-10 . 3-10.
38. Bailon, P., Palleroni, A., Schaffer, C.A., Spence, C.L., Fung, W.J., Porter, J.E., Ehrlich, G.K., Pan, W., Xu, Z.X., Modi, M.W., Farid, A., Berthold, W., and Graves, M. (2001) Rational design of a potent, long - lasting form of interferon: a 40 kDa branched polyethylene glycol - conjugated interferon alpha - 2a for the treatment of hepatitis C . Bioconjug. Chem., 12, 195-202.
39. Bailon, P., and Won, C.Y. (2009) PEG - modifi ed biopharmaceuticals . Expert Opin. Drug Deliv., 6, 1-16.